NanOlogy Chief Medical Officer Gere DiZerega at far left speaking at 2019 BIO CEO and Investor Conference. [Video still: NanOlogy]
NanOlogy said the new patent covers a method of treating cancer by intratumoral administration of large surface area microparticle taxanes in combination with systemic administration of immune checkpoint inhibitors. “The goal is to identify which combinations can increase the immune response, thereby increasing the overall solid tumor response to treatment," said NanOlogy Chief Medical Officer Gere DiZerega.